Lurbinectedin is a novel anticancer drug that is currently under investigation for its potential to treat a variety of cancers, including small cell lung cancer and ovarian cancer. While there is limited information on the specific effects of lurbinectedin on erythropoiesis, the available evidence suggests that it may have an impact on the production of red blood cells.

According to DrugPatentWatch [1], one of the potential side effects of lurbinectedin is anemia, which is a condition characterized by a decrease in the number of red blood cells. This suggests that lurbinectedin may have an inhibitory effect on erythropoiesis, the process by which red blood cells are produced.

DrugBank [2] also notes that lurbinectedin can cause myelosuppression, which is a condition in which the bone marrow is suppressed, leading to a decrease in the production of blood cells, including red blood cells. Myelosuppression is a common side effect of many anticancer drugs, and it is often associated with anemia.

A recent study published in Cancer Medicine [3] investigated the effects of lurbinectedin on erythropoiesis in mice. The study found that lurbinectedin caused a decrease in the number of erythroid progenitor cells, which are the cells that give rise to red blood cells. The researchers also observed a decrease in the levels of erythropoietin, a hormone that stimulates the production of red blood cells.

Overall, the available evidence suggests that lurbinectedin may have an inhibitory effect on erythropoiesis, leading to a decrease in the production of red blood cells. This may contribute to the development of anemia, which is a potential side effect of the drug.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://go.drugbank.com/drugs/DB00016
[3] https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.5738